Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: Chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma

Human Pathology

Volumn 44, Issue 9, 2013, Pages 1859-1866

  Vettukattil, Riyas ^a   Hetland, Thea Eline ^b   Flørenes, Vivi Ann ^b   Kærn, Janne ^b   Davidson, Ben ^b,c   Bathen, Tone F ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Biomarkers; Chemotherapy; Differential diagnosis; Magnetic resonance spectroscopy; Malignant effusions; Metabolomics

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; ALANINE; GLUCOSE; LACTIC ACID; LIPID; PYRUVIC ACID;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE COURSE; EFFUSION; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; OVARY CARCINOMA; PERITONEAL EFFUSION; PLEURA EFFUSION; PROTON NUCLEAR MAGNETIC RESONANCE; RECURRENT DISEASE;

BIOMARKERS; CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; MAGNETIC RESONANCE SPECTROSCOPY; MALIGNANT EFFUSIONS; METABOLOMICS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITIC FLUID; BREAST NEOPLASMS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GLUCOSE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MESOTHELIOMA; METABOLOMICS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION; PROTONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883446235     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.02.009     Document Type: Article

References (34)

1. B. Davidson, P. Firat, and C.W. Michael Serous effusions 2011 Springer New York
2. A. Zhang, H. Sun, and P. Wang Modern analytical techniques in metabolomics analysis Analyst 137 2012 293 300
3. J.K. Nicholson, and J.C. Lindon Systems biology: metabonomics Nature 455 2008 1054 1056
4. A. Zhang, H. Sun, and P. Wang Recent and potential developments of biofluid analyses in metabolomics J Proteomics 75 2012 1079 1088
5. C. Napoli, N. Sperandio, and R.T. Lawlor Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution J Proteome Res 11 2012 1274 1283
6. A. Zhang, H. Sun, and X. Wang Serum metabolomics as a novel diagnostic approach for disease: a systematic review Anal Bioanal Chem 404 2012 1239 1245
7. F.C. Denison, S.I. Semple, and S.J. Stock Novel use of proton magnetic resonance spectroscopy (1HMRS) to non-invasively assess placental metabolism PLoS One 7 2012 e42926
8. A. Bye, R. Vettukattil, and S.T. Aspenes Serum levels of choline-containing compounds are associated with aerobic fitness level: the HUNT-study PLoS One 7 2012 e42330
9. T. Zhang, X. Wu, and M. Yin Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry Clin Chim Acta 413 2012 861 868
10. E. Garcia, C. Andrews, and J. Hua Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe J Proteome Res 10 2011 1765 1771
11. J. Spiliotis, E. Halkia, and D.H. Roukos Ovarian cancer screening and peritoneal carcinomatosis: standards, 'omics' and miRNAs for personalized management Expert Rev Mol Diagn 11 2011 465 467
12. J. Chen, X. Zhang, and R. Cao Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer J Proteome Res 10 2011 2625 2632
13. C.M. Slupsky, H. Steed, and T.H. Wells Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers Clin Cancer Res 16 2010 5835 5841
14. L. Bala, A. Sharma, and R.K. Yellapa (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods NMR Biomed 21 2008 606 614
15. F. Savorani, G. Tomasi, and S.B. Engelsen icoshift: A versatile tool for the rapid alignment of 1D NMR spectra J Magn Reson 202 2010 190 202
16. J. Westerhuis, H. Hoefsloot, and S. Smit Assessment of PLSDA cross validation Metabolomics 4 2008 81 89
17. E.J. van Velzen, J.A. Westerhuis, and J.P. van Duynhoven Multilevel data analysis of a crossover designed human nutritional intervention study J Proteome Res 7 2008 4483 4491
18. R.N. Garrison, R.H. Galloway, and L.S. Heuser Mechanisms of malignant ascites production J Surg Res 42 1987 126 132
19. C. Ludwig, D.G. Ward, and A. Martin Fast targeted multidimensional NMR metabolomics of colorectal cancer Magn Reson Chem 47 Suppl 1 2009 S68 S73
20. P.L. Alo, P. Visca, and M.L. Framarino Immunohistochemical study of fatty acid synthase in ovarian neoplasms Oncol Rep 7 2000 1383 1388
21. T.S. Gansler, W. Hardman III, and D.A. Hunt Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival Hum Pathol 28 1997 686 692
22. S.M. Ueda, K.L. Yap, and B. Davidson Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas J Oncol 2010 2010 285191
23. W. Zhou, W.F. Han, and L.E. Landree Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells Cancer Res 67 2007 2964 2971
24. E.S. Pizer, F.D. Wood, and H.S. Heine Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer Cancer Res 56 1996 1189 1193
25. K.M. Nieman, H.A. Kenny, and C.V. Penicka Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat Med 17 2011 1498 1503
26. Y.C. Chen, G. Pohl, and T.L. Wang Apolipoprotein E is required for cell proliferation and survival in ovarian cancer Cancer Res 65 2005 331 337
27. J.I. Akahira, H. Yoshikawa, and Y. Shimizu Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study Gynecol Oncol 81 2001 398 403
28. H. Bonnefoi, R.P. A'Hern, and C. Fisher Natural history of stage IV epithelial ovarian cancer J Clin Oncol 17 1999 767 775
29. J. Kassis, J. Klominek, and E.C. Kohn Tumor microenvironment: What can effusions teach us? Diagn Cytopathol 33 2005 316 319
30. U.E. Martinez-Outschoorn, R.G. Pestell, and A. Howell Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells Cell Cycle 10 2011 4208 4216
31. T. Egawa-Takata, H. Endo, and M. Fujita Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer Cancer Sci 101 2010 2171 2178
32. W.G. Direcks, S.C. Berndsen, and N. Proost [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study Br J Cancer 99 2008 481 487
33. J.M. Engles, S.A. Quarless, and E. Mambo Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy J Nucl Med 47 2006 603 608
34. C. Cullinane, D.S. Dorow, and M. Kansara An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development Cancer Res 65 2005 9633 9636